Tvardi Therapeutics TVRD
NASDAQ TVRD
$0.93 -0.05 (-5.23%)
As of: Oct 23, 2026 · 2:55 PM EDT

Tvardi Therapeutics (TVRD) Amortization of Deferred Charges (2013)

Updated

Analysis

Tvardi Therapeutics (TVRD) Amortization of Deferred Charges (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,127.89 Bn 1,096.47 Bn 19.71 Bn
2 Johnson & Johnson 635.11 Bn 554.97 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.80 Bn 12.70 Bn
4 Merck 358.24 Bn 312.62 Bn 12.21 Bn
5 Novartis Ag 290.13 Bn 254.12 Bn 11.24 Bn
6 Astrazeneca 265.05 Bn 238.74 Bn 12.86 Bn
7 Amgen 237.87 Bn 193.27 Bn 7.24 Bn
8 Gilead Sciences 194.91 Bn 169.11 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Tvardi Therapeutics 8.91 Mn -99.19 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 39,000.00
Jun 30, 2013 59,000.00
Mar 31, 2013 19,000.00
API Access

Tvardi Therapeutics Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=TVRD&period=max&api_key=YOUR_API_KEY